

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

R. Wright. *et al.*

Appl. No. 10/573,354

Filed: 10 May 2007

For: **Methods of Modulating
Inflammatory Reactions by Modulating
Xanthine Oxidoreductase Activity**

Art Unit: 1612

Examiner: S.M. Basquill

Atty. Docket: 000115-5002

Confirmation No.: 2805

Customer No.: 09629

RESPONSE TO RESTRICTION REQUIREMENT

This paper responds to the Restriction Requirement of 30 April 2010, time for response to which expired 30 May 2010. 30 May 2010 fell on a Sunday, the next business day being 1 June 2010. Thus this paper is timely filed. Applicants do not believe that any extensions of time are necessary to maintain the pendency of this application beyond what may be submitted herewith. If, however, any additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a), and any fees required, including fees for net addition of claims, are hereby authorized to be charged to Deposit Account No. 50-0310.

Applicants would like to thank Examiner Basquill for the phone message left with Applicants' representative on 29 May 2010 that stated that claim 21 is to be included with Group I in the Restriction Requirement.

In response to the Restriction Requirement of 30 April 2010, Applicants elect Group I (claims 1-21) drawn to methods of modulating XOR activity in leukocyte and leukocyte precursor cells, without traverse. The elected invention reads on claims 1-21. In addition, Applicants elect the species of acute lung injury without traverse. Applicants assert that the elected species reads on claims 1-3, 5-12, 14-18, and 20-21. Applicants note that the species election is based on a dependent claim and accordingly assume that if a generic claim is allowed then all further species will be searched as well.